Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Keywords: کارآزمایی بالینی; Human monoclonal antibody; Non-small cell lung cancer (NSCLC); Ramucirumab; Refractory patients; Vascular endothelial growth factor (VEGF); Docetaxel; Clinical trial; Histology; Angiogenesis; Phase 3 clinical trial;